GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlaxoSmithKline (GSK) is conducting a Phase 2b study titled ‘A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)’. The study aims to evaluate the safety and efficacy of sequential therapy using two different doses of DAP/TOM followed by bepirovirsen in patients with chronic Hepatitis B who are already on standard nucleos(t)ide analogue therapy. The goal is to identify the optimal dose for further clinical development and assess the contribution of DAP/TOM to the treatment regimen.
The interventions being tested include two dose levels of Daplusiran/Tomligisiran and bepirovirsen, which are drugs intended to improve treatment outcomes for chronic Hepatitis B patients. The study also includes a placebo group for comparison.
This interventional study uses a randomized, sequential intervention model with double masking to ensure unbiased results. The primary purpose is treatment, focusing on the efficacy and safety of the drug regimen.
The study began on November 11, 2024, with the most recent update on July 25, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results that could impact market dynamics.
For investors, this study could influence GSK’s stock performance, especially if the results show significant improvements in treating chronic Hepatitis B. Positive outcomes could enhance GSK’s competitive position in the pharmaceutical industry, potentially affecting investor sentiment and market share.
The study is ongoing, with further details available on the ClinicalTrials portal.